Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 41 |
| Active Pipeline (Recruiting Now) | 18 (13) |
| Completed vs Stopped Early | 7 / 7 (17.1%) |
| Median Closed Actual Enrollment | 34 participants |
| Physical Hospital Site Disclosure | 99.5% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Erasmus MC | Rotterdam | 14 |
| Erasmus Medical Center | Rotterdam | 12 |
| Leiden University Medical Center | Leiden | 5 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT04430790 | Doxapram Therapy in Preterm Infants (DOXA Trial) | Phase III | RECRUITING |
| NCT07188025 | ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer | Phase III | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Erasmus Medical Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.